March 25, 2021 -- Lassen Therapeutics is collaborating with Cedars Sinai Medical Center to study the role of interleukin 11 (IL-11) signaling and its inhibition in lung fibrosis, along with the potential therapeutic effect of monoclonal antibodies (mAbs) to block IL-11 signaling in preclinical models.
IL-11 is a member of the IL-6 family of cytokines and a mediator of fibrosis. Blocking IL-11 has the potential to be used as a monotherapy or in combination with standard-of-care agents that target other fibroproliferative factors.
The collaboration will focus on idiopathic pulmonary fibrosis, a progressive disease in need of more effective treatments. The collaboration will explore targeting the IL-11 receptor as a potential therapeutic intervention. Lassen has developed a mAb, LASN-01, targeting the IL-11 receptor alpha.
The Cedars Sinai team will be led by Cory Hogaboam, PhD, professor of medicine and a research scientist in the department of medicine at the Women's Guild Lung Institute.
Financial details of the collaboration were not disclosed.
Copyright © 2021 scienceboard.net